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Abstract  
 
Background: The prognostic significance of chest pain is well established in patients with 
coronary artery disease, but still ill defined in primary prevention. Therefore, the aim of our 
analysis was to assess the prognostic value of different forms of chest pain in a large cohort of 
primary care subjects under the conditions of contemporary modalities of care in primary 
prevention, including measurement of serum levels of the biomarker NT-pro-BNP.  
Design: We carried out a post-hoc analysis of the prospective DETECT cohort study.  
Methods: In a total of 5570 unselected subjects, free of coronary artery disease, within the 
55,518 participants of the cross-sectional DETECT study, we assessed chest pain history by a 
comprehensive questionnaire and measured serum NT-pro-BNP levels. Three types of chest 
pain, which were any chest pain, exertional chest pain and classical angina, were defined. 
Major adverse cardiovascular events (MACEs=cardiovascular death, myocardial infarction, 
coronary revascularization procedures) were assessed during a 5-year follow-up period.  
Results: During follow-up, 109 subjects experienced a MACE. All types of reported chest 
pain were associated with an approximately three-fold increased risk for the occurrence of 
incident MACEs, even after adjusting for cardiovascular risk factors. Any form of reported 
chest pain had a similar predictive value for MACEs as a one-time measurement of NT-pro-
BNP. However, adding a single measurement of NT-pro-BNP and the information on chest 
pain resulted in reclassification of approximately 40% of subjects, when compared with risk 
prediction based on established cardiovascular risk factors.  
Conclusions: In primary prevention, self-reported chest pain and a single measurement of NT-
pro-BNP substantially improve cardiovascular risk prediction and allow for risk 
reclassification of approximately 40% of the subjects compared with assessing classical 
cardiovascular risk factors alone.  
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Introduction  
 
Coronary artery disease (CAD) is one of the most prevalent diseases and remains the leading 
cause of death.1 Therefore, the identification of subjects at risk to develop CAD is a major 
goal in primary prevention.  
 
In most cases, angina pectoris is a typical symptom of the initial presentation of CAD.2 
Although the significance of angina is well known in patients with a history of CAD and it is 
the basis for diagnostic and therapeutic decisions in clinical practice,3–6 the prognostic value 
of angina as a predictor of future cardiovascular events is still ill defined in primary 
prevention. As the perception of angina is highly variable, especially for the elderly, women 
and diabetics,7–9 its diagnostic specificity and sensitivity varies between subgroups of 
patients.10,11  
 
Therefore, the aim of our study was to analyse the prognostic value of different types of 
reported chest pain in a large cohort of unselected primary care subjects under the conditions 
of contemporary modalities in primary prevention including measurement of the biomarker 
N-terminal pro-brain natriuretic peptide (NT-pro-BNP), which recently emerged as a valuable 
risk predictor of cardiovascular events in the general population.12,13  
 
Materials and methods  
 
The ‘Diabetes Cardiovascular Risk Evaluation Targets and Essential Data for Commitment of 
Treatment’ (DETECT) trial is a large multistage prospective longitudinal study. In brief, in 
the DETECT study, patients were recruited in a total of 3188 general practitioners (GPs) 
offices evenly distributed throughout Germany at two half-day time points. In detail, during 
the morning working hours (08:00–12:00) on 16 and 18 September 2003, all consecutive 
subjects visiting their GP for diagnostic or therapeutic counselling were recruited into the 
main DETECT study.14 In total, 55,518 subjects were included into the main DETECT study 
addressing the demographic and cardiovascular risk profile of primary care subjects in 
Germany. Thus, the recruitment of all consecutive subjects visiting their primary care 
physician at two predefined half-days indeed represents a cross-sectional snapshot of subjects 
seeking medical advice with their GP throughout Germany. Of the 3188 GPs, 1000 were 
randomly selected to additionally obtain blood samples for standardized laboratory screening 
in 5–10 randomly selected subjects out of the consecutive subjects visiting the GP office at 
the predefined half-day recruitment period.14 This cohort, comprising a total of 7519 subjects, 
was then followed-up for 5 years by their treating GP in order to document incident adverse 
clinical events. Importantly, the cohort of subjects with blood samples did not differ from the 
main 55,518 subjects of the DETECT cohort with respect to demographic and cardiovascular 
risk profiles, thus ascertaining recruitment of a subgroup of subjects representative for the 
entire study cohort, reflecting a truly unselected population.14 For the present analysis, 
subjects with a history of cardiovascular disease were excluded, resulting in a study cohort of 
5570 subjects, in whom clinical chemistry could be performed from blood samples obtained 
at inclusion into the study and correlated with 5-year clinical outcome with respect to incident 
adverse cardiovascular events.14 Supplementary Table 1 illustrates the flowchart of 
recruitment of subjects into the present study.  
 
Baseline examinations  
 
Subjects completed a self-administered questionnaire, which was used to assess demographic 
data, smoking history, family history of coronary artery disease, information on duration and 
severity of cardiovascular risk factors and existing medical as well as non-medical treatment. 
The questionnaire included multiple-choice questions on occurrence, location and 
characteristics of chest pain in order to derive three definitions of chest pain (Supplementary 
Table 2): (1) the standardized and validated ‘Rose angina’,15 which is still used by the World 
Health Organization (WHO) for the definition of angina and was already used in other 
studies;16 (2) the clinically most frequently used ‘exertional chest pain’ and ‘any chest pain’ 
as well as a simple classification of chest pain proposed by the National Institute for Health 
and Clinical Excellence (NICE) guidelines17 on the management of chest pain (typical angina, 
atypical angina and non-anginal chest pain).  
 
Venous blood samples were immediately frozen after collection until the time of the analysis. 
Concentrations of plasma NT-pro-BNP was determined with a sandwich immunoassay on an 
ELECSYS2010 analyser (Roche diagnostics);18 Troponin T (TnT) was measured by the 
Elecsys 2010, third-generation assay (F. Hoffmann-La Roche Diagnostics, Basel, 
Switzerland).  
 
Established cardiovascular risk factors were defined as follows: hypertension was defined as a 
systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90mmHg or treatment with 
antihypertensive medication.19 National Cholesterol Education Program (NCEP) guidelines20 
were applied for the diagnosis of dyslipidemia. Diabetes mellitus (DM) was defined by the 
use of antihyperglycaemic medication or by a fasting plasma glucose level ≥126 mg/dl (7.0 
mmol/l).21 Smoking was defined as current smoking, which includes both active daily 
nicotine abuse and occasional active smoking. An overall risk factor score was calculated 
using the Framingham risk score definitions.22   
 
The DETECT survey received the approval of the Ethics Committee of the Carl Gustav Carus 
Medical Faculty at the Technical University of Dresden (AZ: EK149092003; Date: 16 
September 2003) and was registered at ClinicalTrials.gov (NCT01076608).  
 
Endpoints  
 
At the 5-year follow-up in 2008, state of health and medical history over the follow-up period 
were ascertained. The following endpoints were documented: all cause mortality, mortality of 
cardiovascular cause, occurrence of a myocardial infarction, and manifestation of CAD as 
evidenced by the necessity for coronary revascularization by either coronary artery bypass 
graft (CABG) surgery or percutaneous coronary intervention (PCI). Deaths and known causes 
of deaths were determined by a standardized assessment form by the primary care physician 
and/or by the institution in which the patient was previously treated. Cardiovascular death was 
defined as either sudden (out-of-hospital sudden death) or myocardial infarction- related 
requiring documentation of myocardial infarction by hospital records. Events were verified by 
reviewing the hospital charts of patients with non-fatal myocardial infarction or manifestation 
of CAD due to the necessity for revascularization procedures. Only the first event occurring 
during follow-up was used as an endpoint. In addition to the individual endpoints, a combined 
endpoint of major adverse cardiovascular events (MACEs) was used including death from 
cardiovascular causes, non-fatal myocardial infarction and necessity for coronary 
revascularization by CABG surgery or PCI. In addition we also analysed the data excluding 
revascularization as an endpoint given that reported angina might lead to invasive 
investigations associated with increased revascularization rates.  
 
 
 
Statistical analyses  
 
The association of baseline characteristics as well as the association of different definitions of 
chest pain with the outcome was investigated with the use of Cox proportional hazards 
regression. In addition to crude analysis, hazard ratios were adjusted for demographic factors 
(age and gender) as well as for established risk factors (arterial hypertension, diabetes 
mellitus, hyperlipidemia, obesity and smoking status). Estimates of the C statistic after Cox 
regression models (with 95% confidence intervals), which is the nonparametric estimate of 
the area under the receiver operating characteristic (ROC) curve, for conventional 
cardiovascular risk factors and NT-pro-BNP with different types of chest pain were calculated 
to assess model discrimination.23  
 
In addition, we evaluated the ability to use different questions on chest pain as a diagnostic 
tool, with and without NT-pro-BNP, to reclassify risk, according to previously suggested 
methods.24 Using multivariable risk models with the clinical covariates listed above, we 
calculated the net reclassification Improvement (NRI) and integrated discrimination 
improvement (IDI).24 Subjects were reclassified based on their predicted probabilities for the 
future event based on the addition of chest pain diagnosis and/or biomarker concentration. 
The number of subjects reclassified was assessed by the category free NRI. The difference 
between improvement in average sensitivity and potential increase in average ‘one minus 
specificity’ was calculated be the IDI. Moreover, quantile–quantile plots were constructed in 
order to delineate changes in estimated risk across the entire range of risk.  
 
Results are presented as mean (standard deviation [SD]) for approximately normal distributed 
variables, median (interquartile range) for skewed variables and absolute and relative 
frequencies for categorical variables. Two-sided p-values of less than 0.05 were considered to 
indicate statistical significance. All statistical analyses were conducted with the use of 
STATA 11.  
 
 
Results  
 
The baseline characteristics of the study cohort and the association with MACEs are shown in 
Table 1. The mean age of participants at baseline was 55.6 years (SD 13.8 years; range 18–95 
years). A total of 3465 participants (62.2%) were women; 1900 participants (34.1%) had 
arterial hypertension; 683 patients (12.3%) suffered from diabetes mellitus. Pharmacological 
treatment consisted of angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor 
blockers (ARBs) (23.5%), beta-blockers (20.2%), calcium channel antagonists (9.9%) or 
diuretics (12.4%). None of the subjects had prevalent major cardiovascular disease at 
baseline. During the follow-up period of 5 years, 157 participants (2.8%) died, 137 from non-
cardiac causes, and 20 from cardiovascular cause. A total of 109 (2.0%) subjects experienced 
an incident MACE: in detail, 34 subjects suffered from non-fatal myocardial infarction and 
1.5% (n=86) of the subjects underwent first revascularization procedures by PCI (n=62) or by 
CABG (n=24). As summarized in Table 1, the occurrence of a MACE was associated with the 
classical risk factors for CAD, except smoking. Likewise, subjects suffering from incident 
MACEs during follow-up had significantly higher NT-pro-BNP serum levels as well as a 
higher incidence of elevated Troponin T (TnT) levels. However, it should be noted, that TnT 
levels were above the currently accepted threshold of >0.01 pg/dl in only 0.4% of the entire 
study cohort, thus precluding its use as a clinically meaningful biomarker in primary 
prevention.  
 
All types of reported chest pain, Rose angina, exertional chest pain and any chest pain, as well 
as all NICE angina classifications were associated with an approximately three-fold increased 
risk for the occurrence of MACE (Table 2).15,17 These associations remained unchanged after 
adjustment for age and gender or after additional adjustment for established cardiovascular 
risk factors. Most importantly, exclusion of revascularization from the combined MACE 
endpoint did not alter the results (Table 2), thus documenting that the observed associations 
between different types of reported chest pain and adverse outcome not exclusively driven by 
a higher likelihood of patients with chest pain undergo invasive investigations leading to an 
increased rate of revascularization. None of the types of chest pain increased the hazard ratios 
for all-cause mortality.  
 
As illustrated in Supplementary Table 3, all definitions of reported chest pain were associated 
with a higher prevalence of established cardiovascular risk factors.  
 
The C statistic for Cox regression models increased significantly for the prediction of major 
cardiovascular events, when all types of reported chest pain were separately incorporated into 
a model with the established cardiovascular risk factors (Table 3 and Supplementary Table 5), 
with Rose angina achieving only borderline significance. Moreover, when adding the 
combination of different types of chest pain and NT-pro-BNP to cardiovascular risk factors 
into the risk prediction model, a further significant increase of the C statistics for Cox 
regression models predicting MACEs was observed for all definitions of chest pain. 
Importantly, as summarized in Supplementary Table 6, the addition of NT-pro-BNP serum 
levels specifically increased the C statistics for all forms of NICE angina, whereas no added 
value was observed in subjects without angina.  
 
Finally, we tested the usefulness of adding chest pain, alone and in combination with NT-pro-
BNP serum levels, to conventional cardiovascular risk factors by assessing the number of 
participants reclassified and calculating the IDI on top of the Framingham 10-year risk 
prediction of a major cardiovascular event. As summarized in Table 4, integrated 
discrimination was significantly improved for major cardiovascular events, when all types of 
self-reported chest pain were incorporated into the risk model. Reclassification effect by 
adding the data on exertional chest pain was similar to measuring NT-pro-BNP serum levels 
(Table 4a).  
 
Most importantly, however, combining data on self-reported chest pain and NT-pro-BNP 
serum levels resulted in a further significant improvement of integrated discrimination (Table 
4b). In fact, approximately 40% of the subjects were reclassified either into a higher risk 
category for subjects with events or into a lower risk category in subjects without events. The 
incremental value of adding self-reported chest pain to conventional risk factors for improved 
risk prediction is also illustrated by the quantile–quantile plots shown in Figure 1, which 
demonstrate significant deviations from the line of identity indicating changes in estimated 
risk across the continuum of risk estimates for all types of chest pain.  
 
 
Discussion  
 
The results of the present study demonstrate that in a contemporary nationwide, cross-
sectional sample of primary care subjects, free of any evidence of CAD, all types of reported 
chest pain are associated with an approximately three-fold increase in risk for subsequent 
MACEs during a 5-year follow-up period. Importantly, the predictive power of reporting any 
form of chest pain was similar to the risk predictive value of measuring NT-pro-BNP serum 
levels. However, adding the information on chest pain, and a single measurement of NT-pro-
BNP serum levels resulted in reclassification of approximately 40% of primary care subjects 
when compared with risk prediction based on established cardiovascular risk factors.  
 
The prognostic significance of angina is well established in patients with established CAD. 
However, the few prognostic studies of angina in primary care provided inconclusive 
results.25 A recent study including 1785 subjects with a diagnosis of self-reported angina as 
their first manifestation of ischaemic heart disease demonstrated that men with angina are at 
significantly increased risk of suffering from major adverse cardiovascular events including 
death, acute myocardial infarction and revascularization procedures.26 The present 
approximately three-fold larger study not only extends these observations, but also reveals 
that various forms of reported angina provided similar incremental predictive information 
compared with measuring NT-pro-BNP serum levels. Thus, a simple question regarding the 
presence or absence of angina appears to provide predictive information as robust as NT-pro-
BNP in this setting.  
 
While recent years have witnessed great enthusiasm to use biomarkers as tools to enhance risk 
prediction in primary prevention populations,12,13,27,28 the incremental value of a variety of 
tested biomarkers to enhance risk prediction in primary prevention turned out to be rather 
small and resulted in only small, if any, improvement in discrimination and reclassification.28 
Nevertheless, consistent throughout most of the studies, NT-pro-BNP serum levels 
demonstrated the greatest prognostic value in primary prevention subjects.12,13,27,29–31 The 
results of the present study confirm the utility of NT-pro-BNP as a biomarker for population 
screening. However, importantly, the incremental value of measuring NT-pro-BNP serum 
levels for cardiovascular risk prediction in primary prevention was restricted to subjects 
reporting angina.  
 
Thus, adding NT-pro-BNP and all types of angina to established risk factors led to a further 
significant improvement in integrated discrimination. Thus, a simple question regarding any 
type of chest pain, combined with a single measurement of NT-pro-BNP serum levels results 
in reclassification of 5-year predicted risk of approximately 40% of subjects compared with 
the assessment of classical risk factors alone, providing indeed a time-efficient and feasible 
strategy for risk assessment in primary prevention (Figure 2).  
 
Limitations  
 
The definitions of self-reported angina included previously validated conventional 
categorization of chest pain, such as Rose angina15 as well as the simple NICE guidelines17 
recommended classification, in order to allow for generalization of the results. Thus, we 
cannot rule out that more sophisticated questioning by the primary physician for more precise 
differentiation between the various forms of chest pain would have had an impact on the 
results. However, with respect to time constraints and immense workload in primary care 
physician practices, a time-efficient, standardized questionnaire of self-reported angina 
appears to be sufficient to effectively improve risk prediction, as demonstrated by the results 
of the present study. By design, the present study does not allow for the distinction between 
prevalent and incident cases of chest pain, as no data were obtained regarding the duration of 
chest pain symptoms. Diagnostic work-up and management of subjects with chronic chest 
pain (prevalent cases) may in fact have led to an underestimation of the observed association 
with MACEs. However, the results of our analyses did not change when excluding the 
necessity for revascularization as an endpoint. Thus, eliminating the ‘self-fulfilling-prophecy’ 
that subjects with incident chest pain will be more likely to undergo invasive coronary 
diagnostic work-up resulting in an increased incidence of revascularization procedures 
demonstrated, that the results of the present study are not exclusively driven by the lack of 
differentiation between incident and prevalent cases of angina. Furthermore in line with the 
general office hours of GPs in Germany, subjects were recruited during the morning hours. 
This may have a potential selection bias into the DETECT cohort.  
 
Albeit rather small, the relative number of cardiovascular events in the present study with a 5-
year follow-up period is essentially identical to data from recently published European 
population-based studies in primary prevention,33 suggesting the usefulness of the DETECT 
cohort for cardiovascular risk estimation in a primary prevention population free of CAD.  
 
In summary, the present study is the first to validate self-reported chest pain as a useful tool to 
enhance cardiovascular risk prediction in primary care subjects, given the simplicity of 
retrieving information on chest pain in combination with a single measurement of NT-pro-
BNP for risk assessment in primary care.  
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